AbbVie shares trade near record highs, but reliance on SKYRIZI for one-third of revenue creates a concentration risk that could trigger volatility if growth rates decelerate.
AbbVie's stock is near a 52-week high but faces concentration risk from SKYRIZI slowing, warranting a neutral outlook.
AbbVie stock trades within 1% of its 52-week high, bolstered by a 24% annual gain driven by the rapid expansion of its immunology portfolio. While SKYRIZI and RINVOQ continue to post double-digit growth, the company faces significant concentration risk as older legacy drugs like HUMIRA decline. Investors remain cautious as the market prices in sustained high-growth expectations despite potential competitive and pricing headwinds.
The primary risk is a potential slowdown in the growth rate of SKYRIZI, which currently serves as the company's main engine for revenue expansion while legacy products continue to shrink.
AbbVie is acquiring new immunology assets, such as those from Apogee Therapeutics, to build a growth pipeline that extends into the 2030s.